OncoImmunology

Oncology & Cancer

Inhibited Tyk2 retains anti-cancer activity

Tyrosine kinase 2 (Tyk2) is an enzyme involved in intracellular signalling and has an important role in activating the immune system. But enzymatically active Tyk2 can also promote excessive immune reactions and growth of ...

Oncology & Cancer

New potential for personalized treatments in bowel cancer

Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today in the journal Oncoimmunology.

Oncology & Cancer

Researchers reprogram tumor's cells to attack itself

Inserting a specific strain of bacteria into the microenvironment of aggressive ovarian cancer transforms the behavior of tumor cells from suppression to immunostimulation, researchers at Norris Cotton Cancer Center and the ...

Oncology & Cancer

Researchers develop new anticancer peptide vaccines and inhibitors

(Medical Xpress)—Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort led by investigators at The Ohio State University Comprehensive ...

Oncology & Cancer

Two-step immunotherapy attacks advanced ovarian cancer

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine ...

page 3 from 3